Epigenetic signatures in overgrowth syndromes: Translational opportunities. Issue 4 (16th October 2019)

• Record Type: Journal Article
• Authors: Cytrynbaum, Cheryl; Choufani, Sanaa; Weksberg, Rosanna
• Other Names: Burkardt Deepika guestEditor.; Tatton‐Brown Kate guestEditor.; Dobyns William B. guestEditor.; Graham John guestEditor.
• Is Part Of: American journal of medical genetics. Volume 181:Issue 4(2019)
• Page Start: 491
• Page End: 501
• Publication Date: 2019-10-16
• Subjects: DNA methylation -- DNA methylation signatures -- epigenetics -- overgrowth disorders; Medical genetics -- Periodicals; 616.04205
• DOI: 10.1002/ajmg.c.31745
• Languages: English
• ISSNs: 1552-4868

Abstract

Abstract: In recent years, numerous overgrowth syndromes have been found to be caused by pathogenic DNA sequence variants in "epigenes, " genes that encode proteins that function in epigenetic regulation. Epigenetic marks, including DNA methylation (DNAm), histone modifications and chromatin conformation, have emerged as a vital genome‐wide regulatory mechanism that modulate the transcriptome temporally and spatially to drive normal developmental and cellular processes. Evidence suggests that epigenetic marks are layered and engage in crosstalk, in that disruptions of any one component of the epigenetic machinery impact the others. This interdependence of epigenetic marks underpins the recent identification of gene‐specific DNAm signatures for a variety of disorders caused by pathogenic variants in epigenes. Here, we discuss the power of DNAm signatures with respect to furthering our understanding of disease pathophysiology, enhancing the efficacy of molecular diagnostics and identifying new targets for therapeutics of overgrowth syndromes. These findings highlight the promise of the field of epigenomics to provide unprecedented insights into disease mechanisms generating a host of opportunities to advance precision medicine.